Literature DB >> 2523196

Influence of verapamil on some subcellular defects in diabetic cardiomyopathy.

N Afzal1, G N Pierce, V Elimban, R E Beamish, N S Dhalla.   

Abstract

The effects of verapamil on cardiac myofibrillar adenosinetriphosphatase (ATPase) activity, myosin ATPase, and myosin isoenzyme profile as well as sarcoplasmic reticular Ca2+ uptake and ATPase activities were examined in Sprague-Dawley rats made diabetic with a single injection of streptozotocin (65 mg/kg). Myofibrillar ATPase activity and myosin Ca2+ ATPase activity as well as Ca2+ uptake and Ca2+-stimulated ATPase activities of the sarcoplasmic reticulum were significantly decreased in diabetic hearts in comparison to the control values. The myosin isoenzyme component V3 was prominent in diabetic hearts, whereas V1 isoenzyme was the major myosin component in control hearts. Chronic treatment of diabetic rats with verapamil (8 mg/kg daily for 4-8 wk) resulted in an improvement of the altered myofibrillar ATPase activity, myosin ATPase, myosin isoenzyme distribution, and sarcoplasmic reticular Ca2+-pump activities in ventricular tissue. The ability of verapamil to normalize the observed defects in the subcellular organelles in diabetic cardiomyopathy may be related to its effects in controlling the entry of Ca2+ into the cardiac cell.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523196     DOI: 10.1152/ajpendo.1989.256.4.E453

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

1.  Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction.

Authors:  Harjot K Saini; Qiming Shao; Sorin Musat; Nobuakira Takeda; Paramjit S Tappia; Naranjan S Dhalla
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

Review 2.  Mechanisms of subcellular remodeling in heart failure due to diabetes.

Authors:  Naranjan S Dhalla; Nobuakira Takeda; Delfin Rodriguez-Leyva; Vijayan Elimban
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

3.  Alterations in sarcoplasmic reticulum and mitochondrial functions in diabetic cardiomyopathy.

Authors:  Naranjan S Dhalla; Shashanka Rangi; Shelley Zieroth; Yan-Jun Xu
Journal:  Exp Clin Cardiol       Date:  2012-09

Review 4.  Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment.

Authors:  Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

5.  Differential changes in cardiac myofibrillar and sarcoplasmic reticular gene expression in alloxan-induced diabetes.

Authors:  L Golfman; I M Dixon; N Takeda; D Chapman; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1999-10       Impact factor: 3.396

6.  Diabetic cardiomyopathy: ongoing controversies in 2012.

Authors:  P M Seferović; I Milinković; A D Ristić; J P Seferović Mitrović; K Lalić; A Jotić; V Kanjuh; N Lalić; B Maisch
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

7.  Cardiac sarcolemmal Na(+)-Ca2+ exchange and Na(+)-K+ ATPase activities and gene expression in alloxan-induced diabetes in rats.

Authors:  L Golfman; I M Dixon; N Takeda; A Lukas; K Dakshinamurti; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

Review 8.  Metabolic dysfunction in diabetic cardiomyopathy.

Authors:  Michael Isfort; Sarah C W Stevens; Stephen Schaffer; Chian Ju Jong; Loren E Wold
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

Review 9.  Diabetic cardiomyopathy.

Authors:  F S Fein; E H Sonnenblick
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

10.  Alterations in Ca(2+)-channels during the development of diabetic cardiomyopathy.

Authors:  S L Lee; I Ostadalova; F Kolar; N S Dhalla
Journal:  Mol Cell Biochem       Date:  1992-02-12       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.